Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 22Unknown 4Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

NIH 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 53Genitourinary 6Other hematologic neoplasm 5Dermatologic 4Thoracic 3Sarcoma 2Other solid neoplasm 2Endocrine 2Breast 2Tumor-Agnostic 1Head & Neck 1

Conditions

Melanoma 3Uveal Melanoma 1

Interventions

Nivolumab 25pembrolizumab 21Ipilimumab 15Temozolomide 13toripalimab 12Biopsy 10Imiquimod 8Cyclophosphamide 8Dacarbazine 7Blood Specimen Collection 7camrelizumab 6Chemotherapy, Adjuvant 6trametinib 5dabrafenib 5atezolizumab 5aldesleukin 5Gene Expression Profiling 5Cisplatin 5Aminolevulinic Acid 5fludarabine phosphate 4fludarabine 4durvalumab 4binimetinib 4apatinib 4Tomography, Optical Coherence 4Sorafenib 4Photochemotherapy 4Injections 4Bevacizumab 4tislelizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Unknown × Sorafenib × Dermatologic × Clear all
NCT01377025 2014-12-03

STREAM

University Hospital, Essen

Phase 2 Unknown
200 enrolled
Dermatologic

Uveal Melanoma

NCT00492505 2014-01-10

Sorafenib, Tamoxifen, and Cisplatin in Treating Patients With High-Risk Stage III Melanoma

National Cancer Institute (NCI)

Phase 2 Unknown
200 enrolled
Dermatologic

Melanoma

NCT00538005 2014-01-10

Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
54 enrolled
Dermatologic

Melanoma

NCT00811759 2010-10-07

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

National Cancer Institute (NCI)

Phase 1/2 Unknown
58 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡